Phase II neoadjuvant study of nivolumab alone and in combination with relatlimab or ipilimumab in resectable head and neck cancer (SITC 2026) - Oct 2, 2026 - Abstract #484; Pres time: Nov 7, 2026; 10:00 AM - 08:10 PM; Location: PCC - Lower Level - North Exhibition Halls 4-5-6; No abstract available
Clinical • Combination therapy • P2 data • Head and Neck Cancer • Oncology • Solid Tumor
|
|
Dan Zandberg; Simon Chiosea; Matthew Spector; Henry Thorpe; Hong Wang; Kevin Contrera; Seungwon Kim; Shaum Sridharan; Zahra Kelly; Steven Chinn; Aditi Kulkarni; Brand Matthias; Pragati Upadhyay; Jose Zevallos; Heath Skinner; Lazar Vujanovic; Housaiyin Li; Robert Ferris
|